Table S1. Demographic and neuropathological data of human AD patient and control cases. For each case, the age, gender, disease status, age at onset, disease duration, Braak stage, CERAD neuritic plaque score, frontal cortex neuritic plaque frequency, ApoE genotype, and postmortem interval (PMI) are provided. (XLSX 10 kb
Table S1. Exclusion criteria in the National Alzheimer’s Coordination Center Neuropathology Form. Ta...
Figure S2. Total protein fluorescent signal from blots used for immunoblot analysis. Total protein l...
Table S1. Characteristics of the primary antibodies, immunohistochemistry conditions and expression ...
Table S2. Case Characteristics. Values shown are means ± SD. AD, Alzheimer’s disease; AsymAD, asympt...
Table S1. Sample List. AD, Alzheimer’s disease; AS, asymptomatic Alzheimer’s disease; CT, control; M...
Table S3. List of novel proteins with altered abundances in AD identified in the present study. The ...
Figure S6. Cell Type Population Changes Associated with AD and Correlation with Amyloid and Tau Path...
Figure S1. SDS-PAGE of Brain Homogenates. Dorsolateral prefrontal cortex (DLPFC) brain tissue homoge...
Table S1. iTRAQ quantified human brain proteome of AD individuals and their age-matched control. The...
Table S5. Protein co-expression network analysis by WGCNA. Network analysis of the entire proteomic ...
Table S2. iTRAQ quantified human brain proteome of AD individuals and their age-matched control with...
Figure S7. Differential Protein Abundance between AD and AsymAD. Proteins that were significantly in...
Figure S5. TMT Protein Network Modules Enriched for AD Risk Factors. Graphical representation of the...
Table S1. Clinicopathological characteristics of human Cohort 1. Table S2. Clinicopathological chara...
APP is processed in sporadic AD cases. Human samples were obtained from late-onset AD cases (Braak 6...
Table S1. Exclusion criteria in the National Alzheimer’s Coordination Center Neuropathology Form. Ta...
Figure S2. Total protein fluorescent signal from blots used for immunoblot analysis. Total protein l...
Table S1. Characteristics of the primary antibodies, immunohistochemistry conditions and expression ...
Table S2. Case Characteristics. Values shown are means ± SD. AD, Alzheimer’s disease; AsymAD, asympt...
Table S1. Sample List. AD, Alzheimer’s disease; AS, asymptomatic Alzheimer’s disease; CT, control; M...
Table S3. List of novel proteins with altered abundances in AD identified in the present study. The ...
Figure S6. Cell Type Population Changes Associated with AD and Correlation with Amyloid and Tau Path...
Figure S1. SDS-PAGE of Brain Homogenates. Dorsolateral prefrontal cortex (DLPFC) brain tissue homoge...
Table S1. iTRAQ quantified human brain proteome of AD individuals and their age-matched control. The...
Table S5. Protein co-expression network analysis by WGCNA. Network analysis of the entire proteomic ...
Table S2. iTRAQ quantified human brain proteome of AD individuals and their age-matched control with...
Figure S7. Differential Protein Abundance between AD and AsymAD. Proteins that were significantly in...
Figure S5. TMT Protein Network Modules Enriched for AD Risk Factors. Graphical representation of the...
Table S1. Clinicopathological characteristics of human Cohort 1. Table S2. Clinicopathological chara...
APP is processed in sporadic AD cases. Human samples were obtained from late-onset AD cases (Braak 6...
Table S1. Exclusion criteria in the National Alzheimer’s Coordination Center Neuropathology Form. Ta...
Figure S2. Total protein fluorescent signal from blots used for immunoblot analysis. Total protein l...
Table S1. Characteristics of the primary antibodies, immunohistochemistry conditions and expression ...